MDNA Prostate Mitomic Test

Helomics and MDNA Life Sciences have launched MDNA's Prostate Mitomic Test, a liquid biopsy test for early detection of high-grade prostate cancer independent of prostate-specific antigen and age. The test utilizes the company's Mitomic technology platform which exploits unique biologic characteristics of mitochondrial DNA and has a high negative predictive value which can be used to help clinicians determine which patients have a high-grade tumor that requires immediate intervention, the company said. The laboratory-developed test will be available exclusively through Helomics' clinical lab.